Eris Lifesciences Ltd

Meeting Details

• Date and time: Thursday, Aug 27, 2026, 10:30 AM IST.
• Mode: In-person group meeting.
• Organizer: HBM Partners AG.
• Type: Analyst / Institutional Investor Meeting (in-person).

Participants

• Key company participants: Management representatives present; specific roles not disclosed.

Purpose

• Purpose: Investor interaction; discussion to reference public documents; no UPSI intended.

Meeting Details

• Date/time: Aug 17, 2026, 12:00 PM IST
• Type/Mode: One-on-one, Virtual
• Event/organiser: Tokio Marine Asset Management Co. Ltd.
• Purpose: Analyst/institutional investor meeting

Participants

• Key participants: Management representative from Eris Lifesciences

Purpose

• Purpose: Overview of scheduled investor interaction

Meeting Details

• Date and time: Aug 14, 2026 at 11:00 AM IST.
• Mode: Virtual, one-on-one.
• Event/organiser: Franklin Templeton investor conference.

Participants

• Management representatives: roles not specified.

Purpose

• Purpose: analyst/institutional investor meeting for discussion.

Debt drawdown with Axis Bank

• The company drew down a working capital loan of ₹64.40 crore from Axis Bank.
• Sanction letter executed on 5 August 2026; loan includes second charge on assets.
• Aggregate debt level remains unchanged post-drawdown.
• Size of facility: ₹64.40 crore; relates to Working Capital Term Loan.
• No related party exposure; no governance changes disclosed.

Meeting Details

• Date/time: Aug 4, 2026, 4:00 PM IST; Virtual analyst/institutional meeting organised by Bandhan Mutual Fund.

Participants

• Key company participants: management representatives.

Purpose

• Purpose: participation in investor conference for updates.

Additional Notes

• Schedule indicative and subject to change.

Business Overview

• DBF remains core business with growing Insulin and GLP-1 contributions.
• International business includes Swiss Parenterals; CAPA actions underway and Unit-3 commissioning planned FY28.
• Strategic focus on Eris Bionxt and non-represented Insulin Analogs market entry.

Operational Highlights

• Q1 FY27 revenue 873 cr; EBITDA 296 cr; PAT 143 cr; YoY growth 13% revenue, 14.5% PAT.
• DBF organic growth 14% with 35% EBITDA margin.
• GLP-1 performance: ErisRx unit share 21%; Sundae unit share ~20%.
• Insulin market share in represented pool 16%; five insulin analogs to launch FY28.
• Swiss Parenterals CAPA completion planned; sites audit-ready by Dec-26.
• Unit-3 commissioning targeted FY28.
• Shareholding snapshot: promoter stake ~54% as of Jun-26; major funds holders listed.

Financial Performance

• Revenue 873 cr; EBITDA 296 cr; PAT 143 cr; margins 33.9% and 16.4% respectively.
• Consolidated organic revenue growth 13%; PAT growth 14.5% YoY.
• OCF 77% of EBITDA; capex 88 cr; tax rate 20%.

Capital Structure & Liquidity

• Promoter stake 54.14% as of Jun-26; no debt details disclosed.
• OCF equals 77% of EBITDA, supporting Q1 capex of 88 cr.

Strategic Priorities & Outlook

• Get OAD segment to 70% of market growth.
• Bring Cardiac closer to market growth; momentum recovery.
• Commercialise Eris Bionxt; improve supply margins and realise fiscal benefits.
• Enter non-represented Insulin Analogs market (₹2,309 cr pool, 9.4% growth).
• Maintain Sundae momentum; retain #1 rank in prescriptions and value.
• CAPA completion for Swiss Parenterals; sites audit-ready.
• EU CAPA pipeline intact; Unit-3 commissioning FY28.

Risks & Mitigation

• Margin contraction risk in FY27 due to EU CAPA; clarity post-Q2 FY27.
• CAPA actions underway to mitigate potential margin impact.

Governance & Leadership

• Promoter stake around 54%; no board/leadership changes reported.

Financial results

• Unaudited standalone and consolidated results for quarter ended June 30, 2026 approved; limited review unmodified.

Auditor reviews

• Standalone and consolidated results reviews completed with no qualifications.

Cost auditors

• Re-appointment of M/s Kiran J. Mehta & Co. as Cost Auditors for FY 2026-27 approved.

ESOP

• Issued 35,602 ordinary shares under ESOP 2021 during quarter ended June 30, 2026.

Acquisition

• Acquisition of Branded Probiotics Business from Velbiom Probiotics Limited completed for Rs 50 crore on 31 March 2026.

Labour codes impact

• New Labour Codes increased gratuity and leave liabilities; Rs 17.24 crore consolidated, Rs 14.67 crore standalone.

Taxation impact

• Deferred tax credits due to revised rates; Rs 150 crore consolidated, Rs 18 crore standalone.

Dematerialisation and listing updates

• Dematerialisation requests in the quarter were confirmed to depositories.
• Securities dematerialised were listed on exchanges where previously issued securities are listed.
• Physical certificates received were mutilated and cancelled after verification.
• Name of depository substituted as registered owner within prescribed timelines.
• Registrar and Transfer Agent confirmed handling of dematerialisation requests.